Amendment: Dupilumab Alleviates Itching in Various Dermatological Conditions: Insights from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria - Poll - MDSpire

Amendment: Dupilumab Alleviates Itching in Various Dermatological Conditions: Insights from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria

  • By

  • Gil Yosipovitch

  • Brian S. Kim

  • John Y. Koo

  • Zhen Chen

  • Simmi Wiggins

  • Joseph Zahn

  • Philip Sugerman

  • El-Bdaoui Haddad

  • Sonya L. Cyr

  • March 18, 2026

  • 0 min

Share

Original Source(s)

Amendment: Dupilumab Alleviates Itching in Various Dermatological Conditions: Insights from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria

  • by Gil Yosipovitch, Brian S. Kim, John Y. Koo, Zhen Chen, Simmi Wiggins, Joseph Zahn, Philip Sugerman, El-Bdaoui Haddad, Sonya L. Cyr

  • March 18, 2026

Related Content

Connecting the Diagnostic Dots in HIES

Clinical case report highlights how classic features of STAT3 hyper-IgE syndrome can be routinely missed in pediatric practice

Dupilumab and Lymphoma Risk in AD?

Dupilumab is safe from a lymphoma-risk perspective in atopic dermatitis and other type 2 inflammatory diseases, based on real-world data.

Oral TYK2 Inhibition in Atopic Dermatitis

Phase 2 trial evaluated once-daily oral TYK2 inhibition in adults with moderate to severe AD.